PT1066060E - Celulas estaminais mesenquimais como imunossupressores - Google Patents

Celulas estaminais mesenquimais como imunossupressores

Info

Publication number
PT1066060E
PT1066060E PT99911322T PT99911322T PT1066060E PT 1066060 E PT1066060 E PT 1066060E PT 99911322 T PT99911322 T PT 99911322T PT 99911322 T PT99911322 T PT 99911322T PT 1066060 E PT1066060 E PT 1066060E
Authority
PT
Portugal
Prior art keywords
cells
mesenchineal
immunosupressors
stamina
stem cells
Prior art date
Application number
PT99911322T
Other languages
English (en)
Inventor
Joseph D Mosca
Kevin R Mcintosh
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of PT1066060E publication Critical patent/PT1066060E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/46482—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
PT99911322T 1998-04-03 1999-03-12 Celulas estaminais mesenquimais como imunossupressores PT1066060E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8067898P 1998-04-03 1998-04-03

Publications (1)

Publication Number Publication Date
PT1066060E true PT1066060E (pt) 2003-12-31

Family

ID=22158925

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99911322T PT1066060E (pt) 1998-04-03 1999-03-12 Celulas estaminais mesenquimais como imunossupressores

Country Status (11)

Country Link
US (1) US6797269B2 (pt)
EP (1) EP1066060B1 (pt)
JP (1) JP2002510655A (pt)
AT (1) ATE246938T1 (pt)
AU (1) AU2999199A (pt)
CA (1) CA2326838C (pt)
DE (1) DE69910362T2 (pt)
DK (1) DK1066060T3 (pt)
ES (1) ES2205792T3 (pt)
PT (1) PT1066060E (pt)
WO (1) WO1999051275A2 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323073C (en) * 1998-03-13 2010-06-22 Osiris Therapeutics, Inc. Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2002002638A2 (en) * 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
KR100915482B1 (ko) 2000-12-06 2009-09-03 하리리 로버트 제이 태반 줄기 세포의 회수 방법
EP1362095B1 (en) * 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
NZ528035A (en) * 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
AU2012205269B2 (en) * 2004-03-22 2015-08-27 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
WO2005093044A1 (en) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
SG10202001007TA (en) * 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
ES2452595T3 (es) 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US8455250B2 (en) 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
PL2471904T3 (pl) 2005-12-29 2019-08-30 Celularity, Inc. Populacje komórek macierzystych łożyska
MX348735B (es) 2006-01-13 2017-06-27 Mesoblast Int Sarl Celulas madre mesenquimales que expresan los receptores tnf-alfa.
WO2007087293A2 (en) 2006-01-23 2007-08-02 Athersys, Inc. Mapc therapeutics without adjunctive immunosuppressive treatment
PL2772535T3 (pl) * 2006-05-31 2022-09-05 Children's Medical Center Corporation Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
DK2086556T3 (da) * 2006-11-03 2011-05-09 Aastrom Biosciences Inc Populationer af blandede celler til vævsreparation og separationsteknik til cellebehandling
AU2008216749B2 (en) 2007-02-12 2014-03-13 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
DE102007028687A1 (de) * 2007-06-21 2008-12-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Therapeutische Zusammensetzung zur Behandlung einer Autoimmunerkrankung, umfassend eine autologe Antigenzusammensetzung, sowie Verfahren und Vorrichtungen zur autologen Antikörper- und Antigenproduktion
WO2009023566A2 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2783692B1 (en) 2007-09-28 2019-01-02 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP3109317A1 (en) 2007-10-17 2016-12-28 TXCell Tr1 cells, mesenchymal stem cells and uses thereof
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
WO2009114860A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
MX2011001990A (es) 2008-08-20 2011-03-29 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
CN105796602A (zh) 2008-08-20 2016-07-27 人类起源公司 利用分离的胎盘细胞治疗中风
CN102176919A (zh) 2008-08-22 2011-09-07 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
KR20110086176A (ko) 2008-11-19 2011-07-27 안트로제네시스 코포레이션 양막 유래 부착성 세포
US10098333B2 (en) * 2008-12-09 2018-10-16 University Of Southern California Method for treating an SLE-like autoimmune disease in a human subject consisting of administering stem cells from human exfoliated deciduous teeth (SHED) and erythropoietin (EPO) to said human subject
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
ES2784183T3 (es) * 2009-12-08 2020-09-22 Univ Illinois Procedimientos de uso y aparato para modulación inmunitaria de células madre
ES2646750T3 (es) 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
SI2556145T1 (sl) 2010-04-07 2017-01-31 Anthrogenesis Corporation Angiogeneza z uporabo placentnih matičnih celic
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
SG10201503700WA (en) 2010-05-12 2015-06-29 Abt Holding Co Modulation of splenocytes in cell therapy
NZ605505A (en) 2010-07-13 2015-02-27 Anthrogenesis Corp Methods of generating natural killer cells
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
MX2015000237A (es) 2012-06-27 2015-08-14 Orban Biotech Llc Proteinas de fusion ctla4 para el tratamiento de la diabetes.
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
EP2964238B1 (en) 2013-02-19 2021-01-13 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
HUE052516T2 (hu) 2013-04-12 2021-05-28 Houston Methodist Hospital Szervek javítása transzplantációhoz
WO2014182994A1 (en) 2013-05-10 2014-11-13 Children's Medical Center Corporation Wound healing and tissue engineering
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015088414A1 (en) * 2013-12-13 2015-06-18 Isletone Ab Immunomodulatory compositions
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
KR20150136389A (ko) * 2014-05-27 2015-12-07 삼성전자주식회사 관절염 예방 또는 치료용 조성물, 키트, 및 이를 이용한 관절염 예방 또는 치료 방법
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738852A (en) * 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5747299A (en) * 1994-06-23 1998-05-05 The Board Of Trustees Of The Leland Stanford Junior University Anergy genes

Also Published As

Publication number Publication date
ES2205792T3 (es) 2004-05-01
CA2326838A1 (en) 1999-10-14
US6797269B2 (en) 2004-09-28
WO1999051275A2 (en) 1999-10-14
ATE246938T1 (de) 2003-08-15
EP1066060A2 (en) 2001-01-10
DK1066060T3 (da) 2003-11-24
JP2002510655A (ja) 2002-04-09
EP1066060B1 (en) 2003-08-13
CA2326838C (en) 2008-12-23
WO1999051275A3 (en) 1999-12-09
DE69910362T2 (de) 2004-06-24
AU2999199A (en) 1999-10-25
DE69910362D1 (de) 2003-09-18
US20020044923A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
PT1066060E (pt) Celulas estaminais mesenquimais como imunossupressores
HK1071586A1 (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
WO2004063362A3 (en) Cell cycle progression proteins
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
EA202091566A1 (ru) Содержащая нуклеиновую кислоту липидная наночастица и ее применение
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
PE20050376A1 (es) Anticuerpos dirigidos a m-csf
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
NO331101B1 (no) In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
ES2191702T3 (es) Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
DE69516847D1 (de) Chlorpyrimidine als zwischenprodukte
MXPA06010419A (es) Metodos para modular las respuestas inmunes al modular la funcion tim-1, tim-2 y tim-4.
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
TR200401348T4 (tr) Yapay elyaf halatların kontrol edilmesi için elektrik kontağı
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
DE60044655D1 (de) Angereicherte Zellpopulationen des zentralen Nervensystems
AU2001258373A1 (en) Method for identifying helicobacter antigens
DK1007666T3 (da) Neurturinreceptor
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+
DK1572133T3 (da) Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor